Serfling Georg, Kalscheuer Hannes, Schmid Sebastian M, Lehnert Hendrik
Medizinische Klinik I und Institut für Endokrinologie und Diabetes, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Universität zu Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland.
Internist (Berl). 2019 Sep;60(9):912-916. doi: 10.1007/s00108-019-0654-z.
Technological progress has led to numerous innovations in diagnostic and therapeutic applications in diabetes and will also improve the treatment of patients with diabetes in the future. The first commercially available hybrid closed-loop system has been available in the USA since 2016 and the next developmental step toward a fully automated artificial pancreas has been made. The automated control of the basal insulin secretion provides a stabilization of blood glucose with a reduction of hypoglycemia and improvement of long-term control as indicated by improved hemoglobin A1c levels. Although closed-loop systems are not yet officially available in Germany, patients with type 1 diabetes mellitus already benefit from a new generation of continuous glucose monitoring (CGM) systems. Apart from the increased accuracy these new devices can be used for up to 180 days and do not require daily calibration. This article provides a short overview of the innovations in CGM systems and the current status in the development of the artificial pancreas.
技术进步已在糖尿病的诊断和治疗应用方面带来了众多创新，并且在未来还将改善糖尿病患者的治疗。首款商业化的混合闭环系统自2016年起在美国上市，朝着全自动人工胰腺又迈出了下一步发展步伐。基础胰岛素分泌的自动控制可稳定血糖，减少低血糖情况，并如糖化血红蛋白水平改善所示，提升长期控制效果。尽管闭环系统在德国尚未正式上市，但1型糖尿病患者已从新一代连续血糖监测（CGM）系统中获益。除了准确性提高之外，这些新设备可使用长达180天，且无需每日校准。本文简要概述了CGM系统的创新以及人工胰腺的发展现状。
